shares of adma biologics inc rose nearly 15 on thursday after the biopharmaceutical company reported its firstever quarterly gross profit the ramsey nj company said revenue more than doubled in the third quarter to 207 million and that it generated a positive gross profit for the first time since its inception in 2004 analysts at raymond james raised their rating on adma shares to strong buy from outperform saying they expect the companys momentum to continue into the fourth quarter and 2022 raymond james which has a 5 price target on the stock said adma has solidified its stance as an emerging player in the plasma therapeutics market particularly in an immunoglobulin space that has been growing at an average rate of 115 since 2010 adma shares were recently up 143 to 160